Next-generation immunotherapies for lymphoma: one foot in the future
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next-generation immunotherapies for lymphoma: one foot in the future
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 29, Issue 3, Pages 588-601
Publisher
Oxford University Press (OUP)
Online
2018-01-20
DOI
10.1093/annonc/mdy032
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rationale for stimulator of interferon genes–targeted cancer immunotherapy
- (2017) Thaiz Rivera Vargas et al. EUROPEAN JOURNAL OF CANCER
- LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment
- (2017) Baldur Sveinbjørnsson et al. Future Medicinal Chemistry
- INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
- (2017) A.F. Herrera et al. HEMATOLOGICAL ONCOLOGY
- AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1
- (2017) S.S. Neelapu et al. HEMATOLOGICAL ONCOLOGY
- Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial
- (2017) P. Zinzani et al. HEMATOLOGICAL ONCOLOGY
- BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)
- (2017) R. Chen et al. HEMATOLOGICAL ONCOLOGY
- GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS
- (2017) S.J. Schuster et al. HEMATOLOGICAL ONCOLOGY
- HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001)
- (2017) J. Abramson et al. HEMATOLOGICAL ONCOLOGY
- SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)
- (2017) C.S. Diefenbach et al. HEMATOLOGICAL ONCOLOGY
- Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases
- (2017) Benjamin Frey et al. IMMUNOLOGICAL REVIEWS
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
- (2017) Jeremy S. Abramson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- STING-mediated DNA sensing in cancer immunotherapy
- (2017) Xiang Zhou et al. Science China-Life Sciences
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
- (2016) A. Viardot et al. BLOOD
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
- (2016) X. Wang et al. BLOOD
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- The oncolytic peptide LTX-315 triggers immunogenic cell death
- (2016) H Zhou et al. Cell Death & Disease
- Classical Hodgkin Lymphoma with Reduced 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
- (2016) M. G. M. Roemer et al. Cancer Immunology Research
- Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma
- (2015) I. Sagiv-Barfi et al. BLOOD
- Targetable genetic features of primary testicular and primary central nervous system lymphomas
- (2015) B. Chapuy et al. BLOOD
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
- (2015) Heng Yang et al. CANCER RESEARCH
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Therapeutic cancer vaccines
- (2015) Cornelis J.M. Melief et al. JOURNAL OF CLINICAL INVESTIGATION
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
- (2015) K Cao et al. ONCOGENE
- A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
- (2015) Eric J. Smith et al. Scientific Reports
- Kick-starting the cancer-immunity cycle by targeting CD40
- (2015) P Ellmark et al. OncoImmunology
- Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies
- (2014) Friedhelm R. Schuster et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing
- (2014) Y Liu et al. LEUKEMIA
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
- (2014) P. Muller et al. Cancer Immunology Research
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
- (2013) A. C. West et al. CANCER RESEARCH
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27-Transgenic Mice
- (2013) L.-Z. He et al. JOURNAL OF IMMUNOLOGY
- TLR agonists: our best frenemy in cancer immunotherapy
- (2013) Sabina Kaczanowska et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies
- (2013) Samuel T Workenhe et al. MOLECULAR THERAPY
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
- (2012) Ariane Thielens et al. CURRENT OPINION IN IMMUNOLOGY
- Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
- (2011) Giuseppe Nocentini et al. BRITISH JOURNAL OF PHARMACOLOGY
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T Cells
- (2010) Drew J. Roberts et al. JOURNAL OF IMMUNOTHERAPY
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
- (2009) R. Houot et al. BLOOD
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
- (2009) Atsuko Soeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
- (2008) A. Bashey et al. BLOOD
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- (2008) B. G. Till et al. BLOOD
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
- (2008) X. Zhou et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started